GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC

EIN: 134128413 501(c)(3) Medical Research

NEW YORK, NY

Total Revenue
$60,240,486
Total Expenses
$55,378,579
Total Assets
$197,319,541
Net Assets
$171,699,550
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
2000
Legal Domicile
DE
Principal Officer
MELVIN SPIGELMAN
Phone
2122277540
Tax Period
2023-01-01 to 2023-12-31

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC, founded in 2000, is a mid-sized nonprofit in the Medical Research sector that reported $60.2M in total revenue in fiscal year 2023. Expenses of $55.4M left a modest 8% surplus.

Mission

TO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $49,796,816
Program Service Revenue $0
Investment Income $8,182,816
Other Revenue $2,260,854
TOTAL REVENUE $60,240,486

Expense Breakdown

Grants Paid $278,450
Salaries & Benefits $17,365,566
Fundraising Expenses $1,260,040
Program Expenses $48,843,533
Other Expenses $37,734,563
TOTAL EXPENSES $55,378,579

Year-over-Year Comparison

2023 2022 Change
Revenue $60,240,486 $56,212,963 +0.1%
Expenses $55,378,579 $55,785,890 0.0%
Net Income $4,861,907 $427,073 +10.4%
Key Indicators
✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
10
Independent Members
9
Employees
55
Volunteers
9

Governance Policies

✗ Conflict of Interest Policy
✗ Whistleblower Policy
✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School
✗ Operated a Hospital
✗ Provided First Class Travel
✗ Reported Conflict of Interest
✗ Reported Asset Diversion
✗ Excess Benefit Transaction
✗ Made Political Expenditures
✗ Engaged in Lobbying
✗ Operated Donor Advised Fund
✗ Maintained Art Collections
✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
5
$2,066,004
Total Directors
10
$1,028,783
Key Employees
4
$2,292,083
Highest Compensated
5
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
DR MELVIN SPIGELMAN PRESIDENT/CEO 45.0
Officer Director
$921,007 $107,776 $1,028,783
DR NADER FOTOUHI SR. VP, CHIEF SCIENTIFIC OFF. 45.0
Key Emp
$545,570 $114,466 $660,036
DR EUGENE SUN SR. VP, RESEARCH & DEV'T 45.0
Key Emp
$562,265 $86,040 $648,305
MARIA BEUMONT VP, CHIEF MEDICAL OFFICER 45.0
Key Emp
$483,078 $81,608 $564,686
COLLEEN PERO SECRETARY/CAO 45.0
Officer
$457,040 $68,861 $525,901
ROBERT LORETTE SR. VP, BUSINESS DEVELOPMENT 45.0
Highest
$437,313 $83,939 $521,252
ANGELA VANDERPLOEG TREASURER/CFO 45.0
Officer
$411,013 $100,307 $511,320
SANDEEP JUNEJA SR. VP, MARKET ACCESS 45.0
Highest
$406,262 $99,678 $505,940
KATHLEEN SCHOSTACK SR. VP, PROG. & ALLIANCE MGMT 45.0
Highest
$419,997 $82,950 $502,947
SALAH FORAIDA SR. DIRECTOR, MEDICAL AFFAIRS 45.0
Highest
$418,194 $50,829 $469,023
RAJNEESH TANEJA VP, PHARMACEUTICAL PROD. DEV'T 45.0
Highest
$360,974 $77,744 $438,718
PIETRO TURILLI SR.VP, EXTERNAL AFFAIRS 45.0
Key Emp
$327,992 $91,064 $419,056
DAVID NORTON CHAIR 3.0
Officer Director
$0 $0 $0
ARIEL PABLOS-MENDEZ VICE CHAIR 3.0
Officer Director
$0 $0 $0
ERIC GOOSBY DIRECTOR 3.0
Director
$0 $0 $0
RASHA HIBRI DIRECTOR 3.0
Director
$0 $0 $0
SUNDAR KODIYALAM DIRECTOR 3.0
Director
$0 $0 $0
MARIO RAVIGLIONE DIRECTOR 3.0
Director
$0 $0 $0
KIM SCHWARTZ DIRECTOR 3.0
Director
$0 $0 $0
MITCHELL WARREN DIRECTOR 3.0
Director
$0 $0 $0
RATAN WATAL DIRECTOR eff. 1/1/2023 3.0
Director
$0 $0 $0
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2024 No data No data No data No data
2023 $60,240,486 $55,378,579 $197,319,541 $4,861,907
2022 $56,212,963 $55,785,890 $176,686,879 $427,073
2021 $58,653,379 $57,430,605 $187,560,796 $1,222,774
2020 $61,267,452 $61,720,389 $191,155,661 $-452,937
2019 $174,873,899 $69,535,079 $189,418,881 $105,338,820
2018 $63,283,490 $60,315,645 $75,171,538 $2,967,845
Explore More Nonprofits
→Top 100 Nonprofits in New York →Largest U.S. Nonprofits →Best Rated Nonprofits →Most Efficient Nonprofits

Compare GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC with other nonprofits in New York and across the country.

We Value Your Privacy
We use cookies and similar technologies to analyze site traffic and improve your experience. By clicking "Accept All", you consent to our use of cookies for analytics and measurement.